Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U01 Substudy 01I in previously treated stage IV squamous non-small cell lung cancer
CTR20254104Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Jan 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel in Pulmonary squamous cell carcinoma, sponsored by Merck & Co.. Started Jan 2026; status: active.
02
Drugs
docetaxel
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on CTR20254104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254104.